Haig G - Search Results

1

Language trees with sampled ancestors support a hybrid model for the origin of Indo-European languages.

Heggarty P, Anderson C, Scarborough M, King B, Bouckaert R, Jocz L, Kümmel MJ, Jügel T, Irslinger B, Pooth R, Liljegren H, Strand RF, Haig G, Macák M, Kim RI, Anonby E, Pronk T, Belyaev O, Dewey-Findell TK, Boutilier M, Freiberg C, Tegethoff R, Serangeli M, Liosis N, Stroński K, Schulte K, Gupta GK, Haak W, Krause J, Atkinson QD, Greenhill SJ, Kühnert D, Gray RD. Heggarty P, et al. Among authors: haig g. Science. 2023 Jul 28;381(6656):eabg0818. doi: 10.1126/science.abg0818. Epub 2023 Jul 28. Science. 2023. PMID: 37499002

2

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.

Haig GM, Wang D, Zhao J, Othman AA, Bain EE. Haig GM, et al. J Clin Psychiatry. 2018 May/Jun;79(3):16m11162. doi: 10.4088/JCP.16m11162. J Clin Psychiatry. 2018. PMID: 28922590 Clinical Trial.

3

Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. Keefe RSE, et al. Among authors: haig gm. JAMA Psychiatry. 2017 Aug 1;74(8):807-814. doi: 10.1001/jamapsychiatry.2017.1574. JAMA Psychiatry. 2017. PMID: 28636694 Free PMC article.

4

Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).

Hudzik TJ, Basso AM, Lynch JJ 3rd, Bracken WM, Mohler EG, Kohlhaas KL, Xu H, Haig G, Gault L. Hudzik TJ, et al. Among authors: haig g. Pharmacol Biochem Behav. 2017 Jul;158:22-31. doi: 10.1016/j.pbb.2017.05.010. Epub 2017 Jun 1. Pharmacol Biochem Behav. 2017. PMID: 28579351 Free article.

5

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.

Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Georgiades A, et al. Among authors: haig g. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20. Schizophr Res. 2017. PMID: 28433500 Clinical Trial.

6

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Haig G, Wang D, Othman AA, Zhao J. Haig G, et al. Neuropsychopharmacology. 2016 Nov;41(12):2893-2902. doi: 10.1038/npp.2016.101. Epub 2016 Jun 20. Neuropsychopharmacology. 2016. PMID: 27319970 Free PMC article. Clinical Trial.

7

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA. Haig GM, et al. Am J Psychiatry. 2016 Aug 1;173(8):827-35. doi: 10.1176/appi.ajp.2015.15010093. Epub 2016 Mar 4. Am J Psychiatry. 2016. PMID: 26940805 Clinical Trial.

8

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.

Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. Keefe RS, et al. Among authors: haig gm. Schizophr Bull. 2016 Jan;42(1):19-33. doi: 10.1093/schbul/sbv111. Epub 2015 Sep 11. Schizophr Bull. 2016. PMID: 26362273 Free PMC article.

9

Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.

Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RS. Hufford MR, et al. Among authors: haig g. Schizophr Res. 2014 Oct;159(1):205-10. doi: 10.1016/j.schres.2014.07.018. Epub 2014 Aug 6. Schizophr Res. 2014. PMID: 25108773

10

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.

Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA. Haig GM, et al. J Alzheimers Dis. 2014;42(3):959-71. doi: 10.3233/JAD-140291. J Alzheimers Dis. 2014. PMID: 25024314 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page